Health Catalyst (NASDAQ:HCAT) price target cut to $2.00 by analysts at Citigroup. August 11, 2026 Key points. * Citigroup cut Health Catalyst's price target from $2.50 to $2.00 while maintaining a "neutral" rating, implying roughly 12% upside from the prior close. * Analyst sentiment remains mixed but leans toward caution: MarketBeat reports a consensus "Hold" rating and an average price target of $2.95, with four Buys, eight Holds, and one Sell. * Health Catalyst reported quarterly EPS of $0.04, exceeding the $0.03 estimate, and revenue of $70.49 million versus the $69.09 million consensus; however, the company continues to post substantial losses and analysts forecast a full-year loss. * Five stocks we like better than Health Catalyst. Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price target decreased by stock analysts at Citigroup from $2.50 to $2.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Citigroup's target price points to a potential upside of 12.04% from the stock's previous close. A number of other research firms also recently commented on HCAT. Stephens dropped their price target on shares of Health Catalyst from $2.00 to $1.75 and set an "equal weight" rating on the stock in a research report on Tuesday, May 12th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Health Catalyst in a research note on Monday, May 11th. Canaccord Genuity Group boosted their target price on Health Catalyst from $2.00 to $3.00 and gave the stock a "buy" rating in a report on Tuesday, July 21st. Weiss Ratings upgraded Health Catalyst from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company increased their price target on Health Catalyst from $1.00 to $1.75 and gave the company an "equal weight" rating in a research note on Friday, June 26th. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $2.95. Health Catalyst stock performance. Shares of NASDAQ:HCAT traded up $0.07 on Tuesday, hitting $1.78. The company's stock had a trading volume of 1,920,062 shares, compared to its average volume of 1,116,998. Health Catalyst has a 12 month low of $0.96 and a 12 month high of $3.80. The company has a market capitalization of $134.34 million, a price-to-earnings ratio of -0.49 and a beta of 1.55. The stock's 50-day moving average is $1.99 and its two-hundred day moving average is $1.70. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.69 and a current ratio of 1.69. Discover more Stock average calculator Dividend screener tool Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.57% and a negative net margin of 90.61%.The company had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. On average, equities research analysts forecast that Health Catalyst will post -0.25 EPS for the current year. Hedge funds weigh in on Health Catalyst. Several hedge funds have recently made changes to their positions in the business. HighMark Wealth Management LLC grew its position in Health Catalyst by 139.0% in the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company's stock worth $1,772,000 after buying an additional 431,200 shares during the last quarter. UBS Group AG lifted its position in shares of Health Catalyst by 10.0% during the 3rd quarter. UBS Group AG now owns 197,314 shares of the company's stock valued at $562,000 after acquiring an additional 17,887 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Health Catalyst by 26.2% during the 2nd quarter. American Century Companies Inc. now owns 148,858 shares of the company's stock valued at $561,000 after acquiring an additional 30,884 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Health Catalyst by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 101,986 shares of the company's stock worth $384,000 after acquiring an additional 12,127 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Health Catalyst by 7.3% during the 4th quarter. Barclays PLC now owns 148,186 shares of the company's stock worth $354,000 after acquiring an additional 10,100 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock. About Health Catalyst. Health Catalyst NASDAQ: HCAT is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information. The core of Health Catalyst's offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources - from electronic health records to claims and patient-generated data - into a single analytics environment. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Health Catalyst, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list. While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Why Health Catalyst (HCAT) shares are trading lower today. Adam hejl /. August 7, 2026 What happened? Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations. For the upcoming third quarter, Health Catalyst expects revenue of $55.5 million, a sharp sequential decline from the $70.49 million reported for the second quarter, which itself was down 12.7% year over year. The company also reduced its full-year 2026 revenue guidance to $247.5 million at the midpoint, a 5.7% decrease from its previous forecast. This bleak outlook overshadowed the second-quarter results, in which the company's adjusted earnings per share met analysts' estimates, signaling significant challenges ahead. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it's free. What is the market telling us. Health Catalyst's shares are extremely volatile and have had 55 moves greater than 5% over the last year. But moves this big are rare even for Health Catalyst and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 6.4% on the news that the software sector caught a massive tailwind, fueled by easing geopolitical tensions and a fresh wave of AI-driven M&A. Over the weekend, President Trump abruptly called off a planned military offensive against Iran. Yielding to pressure from Gulf allies, the administration shifted toward diplomatic talks to reopen the Strait of Hormuz. This critical de-escalation relieved pressure on global energy markets and inflation expectations, accelerating a drop in Treasury yields. For software, this shifting macro backdrop is the perfect catalyst. Lower interest rates reduce the discount rate applied to expected future cash flows, driving capital back into growth-oriented tech equities. Furthermore, a lower-yield environment provides cheaper borrowing costs to fund ongoing AI development and the aggressive acquisitions currently sweeping the industry. Strategic dealmaking continues to accelerate. Yellow.ai, a global leader in enterprise agentic AI, announced a $550 million SPAC merger with Bluerock Acquisition Corp to go public under the ticker "YAI." Meanwhile, financial automation leader AutoRek acquired Grath to integrate its AI-driven reconciliation and compliance technology. Health Catalyst is down 24.3% since the beginning of the year, and at $1.73 per share, it is trading 53.3% below its 52-week high of $3.69 from August 2025. Investors who bought $1,000 worth of Health Catalyst's shares 5 years ago would now be looking at only $29.92. ALSO WORTH WATCHING: Nvidia's Quiet Partner. Nvidia's chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don't make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Health Catalyst, a healthcare data analytics company, reported Q2 2026 revenue of $70.49 million, topping analyst estimates by 2.1% despite a 12.7% year-on-year decline. The company's non-GAAP profit of $0.04 per share met expectations. However, the stock dropped 25.5% following disappointing forward guidance. Next quarter's revenue projection of $55.5 million came in 10.7% below analyst estimates, representing a 27.3% year-on-year decline. The company also lowered its full-year revenue guidance to $247.5 million from $262.5 million. Full-year EBITDA guidance of $18.25 million fell short of analyst estimates of $32.09 million. Chief executive Ben Albert said the company "delivered a very productive second quarter, exceeding the high end of our revenue guidance".